These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27003514)

  • 21. Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors.
    Jing CB; Fu C; Prutsch N; Wang M; He S; Look AT
    Leukemia; 2020 Nov; 34(11):2992-3006. PubMed ID: 32572188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TET proteins and 5-methylcytosine oxidation in hematological cancers.
    Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
    Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tet2-mutated myeloid progenitors possess aberrant in vitro self-renewal capacity.
    Kunimoto H; Fukuchi Y; Sakurai M; Takubo K; Okamoto S; Nakajima H
    Blood; 2014 May; 123(18):2897-9. PubMed ID: 24786459
    [No Abstract]   [Full Text] [Related]  

  • 24. [TET2 dysregulation in hematologic malignancies].
    Sakata-Yanagimoto M
    Rinsho Ketsueki; 2014 Oct; 55(10):1893-902. PubMed ID: 25297753
    [No Abstract]   [Full Text] [Related]  

  • 25. Mutation in TET2 in myeloid cancers.
    Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
    N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions.
    La Starza R; Crescenzi B; Nofrini V; Barba G; Matteucci C; Brandimarte L; Pierini V; Testoni N; Musto P; Paolini S; Gianfelici V; Storlazzi CT; Pierini A; Berchicci L; Gorello P; Mecucci C
    Leuk Res; 2012 Jan; 36(1):37-41. PubMed ID: 21920603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibiotic treatment ameliorates Ten-eleven translocation 2 (TET2) loss-of-function associated hematological malignancies.
    Zeng H; He H; Guo L; Li J; Lee M; Han W; Guzman AG; Zang S; Zhou Y; Zhang X; Goodell MA; King KY; Sun D; Huang Y
    Cancer Lett; 2019 Dec; 467():1-8. PubMed ID: 31563562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TET genes: new players in DNA demethylation and important determinants for stemness.
    Mohr F; Döhner K; Buske C; Rawat VP
    Exp Hematol; 2011 Mar; 39(3):272-81. PubMed ID: 21168469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TET2 Mutation in Adult T-Cell Leukemia/Lymphoma.
    Shimoda K; Shide K; Kameda T; Hidaka T; Kubuki Y; Kamiunten A; Sekine M; Akizuki K; Shimoda H; Yamaji T; Nakamura K; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Kitanaka A
    J Clin Exp Hematop; 2015; 55(3):145-9. PubMed ID: 26763362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FISHing for TET2: Utility of FISH for TET2 deletions detection in clinical samples.
    Pignataro DS; Abdel-Wahab O
    Leuk Res; 2012 Jan; 36(1):25-6. PubMed ID: 21917313
    [No Abstract]   [Full Text] [Related]  

  • 31. TET2 mutation in diffuse large B-cell lymphoma.
    Kubuki Y; Yamaji T; Hidaka T; Kameda T; Shide K; Sekine M; Kamiunten A; Akizuki K; Shimoda H; Tahira Y; Nakamura K; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Kitanaka A; Shimoda K
    J Clin Exp Hematop; 2017; 56(3):145-149. PubMed ID: 28331128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm.
    Jardin F; Ruminy P; Parmentier F; Troussard X; Vaida I; Stamatoullas A; Leprêtre S; Penther D; Duval AB; Picquenot JM; Courville P; Capiod JC; Tilly H; Bastard C; Marolleau JP
    Br J Haematol; 2011 May; 153(3):413-6. PubMed ID: 21275969
    [No Abstract]   [Full Text] [Related]  

  • 33. [Significance of TET2 mutations in myeloid and lymphoid neoplasms].
    Chiba S
    Rinsho Ketsueki; 2016 Jun; 57(6):715-22. PubMed ID: 27384850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A vicious interplay between genetic and environmental insults in the etiology of blood cancers.
    Migliaccio AR
    Exp Hematol; 2018 Mar; 59():9-13. PubMed ID: 29248611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models.
    Ono R; Masuya M; Inoue N; Shinmei M; Ishii S; Maegawa Y; Maharjan BD; Katayama N; Nosaka T
    PLoS One; 2021; 16(3):e0248425. PubMed ID: 33705482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Aberrant cytosine hydroxymethylation in hematologic malignancies].
    Sakata-Yanagimoto M; Chiba S
    Rinsho Ketsueki; 2013 May; 54(5):423-30. PubMed ID: 23727679
    [No Abstract]   [Full Text] [Related]  

  • 37. Myeloid disorders arise in Dnmt3a-null marrow.
    Delwel R
    Blood; 2015 Jan; 125(4):585-6. PubMed ID: 25614634
    [No Abstract]   [Full Text] [Related]  

  • 38. Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.
    Palam LR; Mali RS; Ramdas B; Srivatsan SN; Visconte V; Tiu RV; Vanhaesebroeck B; Roers A; Gerbaulet A; Xu M; Janga SC; Takemoto CM; Paczesny S; Kapur R
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clonal haematopoiesis: A concise review].
    Danlos FX; Papo M; Micol JB
    Rev Med Interne; 2019 Oct; 40(10):684-692. PubMed ID: 31126662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TET2, a tumor suppressor in hematological disorders.
    Mercher T; Quivoron C; Couronné L; Bastard C; Vainchenker W; Bernard OA
    Biochim Biophys Acta; 2012 Apr; 1825(2):173-7. PubMed ID: 22240200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.